The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
 
Yasunobu Ishizuka
No Relationships to Disclose
 
Yukiya Narita
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Ono Pharmaceutical (Inst)
 
Tomoki Sakakida
No Relationships to Disclose
 
Munehiro Wakabayashi
No Relationships to Disclose
 
Hiroyuki Kodama
No Relationships to Disclose
 
Kazunori Honda
Consulting or Advisory Role - Eisai
Research Funding - Pfizer (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)
 
Masashi Ando
Honoraria - Chugai Pharma; Eisai; Mundipharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masahiro Tajika
Speakers' Bureau - Bristol-Myers Squibb Japan; Otsuka
Research Funding - Pfizer (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Solasia Pharma
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)